What do Cochrane systematic reviews say about interventions for age-related macular degeneration?

被引:3
|
作者
Mozetic, Vania [1 ,2 ]
Pacheco, Rafael Leite [1 ,3 ,4 ]
Cruz Latorraca, Carolina de Oliveira [1 ,4 ]
Yu Ogasawara Lee, Fernanda Chin [1 ,5 ]
Borges Gomes, Joao Victor [1 ,5 ,6 ]
Riera, Rachel [1 ,5 ]
机构
[1] Cochrane Brazil, Sao Paulo, SP, Brazil
[2] Inst Dante Pazzanese Cardiol, Sao Paulo, SP, Brazil
[3] Ctr Univ Sao Camilo, Sao Paulo, SP, Brazil
[4] Univ Fed Sao Paulo, Evidence Based Hlth Program, UNIFESP, Sao Paulo, SP, Brazil
[5] Univ Fed Sao Paulo, UNIFESP, EPM, Sao Paulo, SP, Brazil
[6] Hosp Sirio Libanes, Ctr Hlth Technol Assessment, Sao Paulo, SP, Brazil
来源
SAO PAULO MEDICAL JOURNAL | 2019年 / 137卷 / 06期
关键词
Cochrane reviews; Age-related macular degeneration; Systematic reviews; Overview;
D O I
10.1590/1516-3180.2019.010317092019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Age-related macular degeneration (AMD) is the third largest cause of blindness worldwide, accounting for 8.7% of all cases. A considerable number of preventive or therapeutic interventions have been used for AMD. OBJECTIVE: This study presents a critical view of the interventions that have been assessed through Cochrane systematic reviews. DESIGN AND SETTING: Review of systematic reviews, conducted in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de Sao Paulo (UNIFESP). METHODS: Review of Cochrane systematic reviews about interventions for AMD. RESULTS: The 18 systematic reviews included assessed the effects of surgical techniques, laser/photo/radiotherapy, intravitreal injections, systemic drugs and phytotherapy/vitamins/supplements. CONCLUSION: The Cochrane systematic reviews found evidence that use of bevacizumab, ranibizumab, pegaptanib, laser photocoagulation, photodynamic therapy and multivitamin compounds may present some benefits for treating AMD. There was insufficient evidence for supporting the use of macular translocation, submacular surgery, steroid implantation, radiotherapy, intravitreal aflibercept, interferon alfa, statins or omega-3 fatty acids for treating AMD; or the use of multivitamin antioxidant vitamins or mineral supplementation for preventing AMD. Future randomized controlled trials are imperative to reduce the uncertainty in several clinical questions regarding AMD.
引用
收藏
页码:530 / 542
页数:13
相关论文
共 50 条